Molecular & Cellular Proteomics · 2025 · 10 citations · 29 references
PharmacyBiochemistryDrug DiscoveryMass Spectrometric AnalysisProteomicsLabel-free QuantificationMass SpectrometryMass Spectrometry Data AnalysisPeptide AnalysisProteomic ProfilingQuantitative ProteomicsMass Spectrometry ProteomicsMs3-based QuantificationMultiplexed Proteome QuantificationMultiplexed ProteomicsPeptide Mass SpectrometryProtein Mass SpectrometryRatio CompressionTandem Mass Spectrometry
Ongoing advancements in instrumentation has established mass spectrometry (MS) as an essential tool in proteomics research and drug discovery. The newly released Asymmetric Track Lossless (Astral) analyzer represents a major step forward in MS instrumentation. Here, we evaluate the Orbitrap Astral mass spectrometer in the context of tandem mass tag (TMT)-based multiplexed proteomics and activity-based proteome profiling, highlighting its sensitivity boost relative to the Orbitrap Tribrid platform-50% at the peptide and 20% at the protein level. We compare TMT data-dependent acquisition and label-free data-independent acquisition on the same instrument, both of which quantify over 10,000 human proteins per sample within 1 h. TMT offers higher quantitative precision and data completeness, while data-independent acquisition is free of ratio compression and is thereby more accurate. Our results suggest that ratio compression is prevalent with the high-resolution MS2-based quantification on the Astral, while real-time search-based MS3 quantification on the Orbitrap Tribrid platform effectively restores accuracy. Additionally, we benchmark TMT-based activity-based proteome profiling by interrogating cysteine ligandability. The Astral measures over 30,000 cysteines in a single-shot experiment, a 54% increase relative to the Orbitrap Eclipse. We further leverage this remarkable sensitivity to profile the target engagement landscape of FDA-approved covalent drugs, including sotorasib and adagrasib. We herein provide a reference for the optimal use of the advanced MS platform.
29
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations
Medicine, Oncology, Pharmacology +14
Quantitative reactivity profiling predicts functional cysteines in proteomes
Eranthie Weerapana, Chu Wang, Gabriel M. Simon et al. · Nature · 2010 · 1.7K citations · Full text